The San Carlos, California-based molecular diagnostic company reported total revenue of $45.1 million in Q2, up from $35.8 million in Q2 2014.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
The bank said Natera's SNP-based NIPT technology would give it an advantage as it seeks to gain share in the average-risk pregnancy market.
The company provided preliminary 2015 revenue guidance of $175 million to $190 million.
The goal is to detect both clonal and subclonal variations and to demonstrate how Natera's technology can help improve cancer patient care and treatment outcomes.
The $180 million offering is well above the firm's initial target for proceeds of $100 million.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The deal will allow LifeLabs to perform Natera's Panorama NIPT in Canada and follows a prior agreement for LifeLabs to distribute the test in that country.
Three new studies, published online in the New England Journal of Medicine, shed light on how NIPT may be best integrated into clinical care for all pregnant women.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.